| Overview |
| bsm-54756r |
| LPP Recombinant Antibody |
| WB, IHC-P, IHC-F, IF |
| Human |
| Specifications |
| Unconjugated |
| Rabbit |
| Synthetic peptide within N-terminal Human LPP. |
| Recombinant |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
| Store at -20°C for 12 months. |
| Target |
| 4026 |
| Q93052 |
| Cytoplasm, Nucleus, Cell membrane, Cell junction |
| DKFZp779O0231 antibody, FLJ30652 antibody, FLJ41512 antibody, LIM domain containing preferred translocation partner in lipoma antibody, LIM domain-containing preferred translocation partner in lipoma antibody, LIM protein antibody, Lipoma preferred partner antibody, Lipoma-preferred partner antibody, lpp antibody, LPP_HUMAN antibody |
| LPP (LIM containing lipoma preferred partner), is a scaffolding protein which contains three LIM domains at its carboxy terminus, preceded by a proline rich pre LIM region containing a number of protein interaction domains. LPP localizes to sites of cell adhesion, such as focal adhesions and cell-cell contacts and may be involved in cell-cell adhesion and cell motility. LPP also shuttles through the nucleus and may function as a transcriptional co-activator. The human LPP gene maps to chromosomal location 3q28, and preferentially translocates to the HMGIC gene in a subclass of human benign mesenchymal tumors known as lipomas. Alternate splicing results in multiple transcript variants. |
| Application Dilution |
| WB |
1:300-5000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF |
|
Powered by Bioz